RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Teuto or Verdemed?
Lol, it seems you are reading my comments but interpreting them wrong. I never said Keith was a good operator. My comments regarding Keith have all been about vision and strategy. He was at the helm of LABS while those decisions were made. Period. He has vision and seems to be a good strategizer. Imo, that is why he is being moved to the board. And this move, imo, signals LABS is shopping itself an acquirer when you consider all other events strangely happening during the same period.
Why is Keith being moved to the board now vs 2 years ago when Pidduck came in, or 1 year ago? According to you, he has always been useless operationnaly, why wasn't he canned before? Why would'nt Keith be shuffled to the board in one year or two? Why now? Nothing factual leads to think he did something bad. At least not him personnaly.
Keith received 3.5M RSUs and options in december 2023. Does that look like someone not doing his job? He received more than anybody except Pidduck.
Also, as I said before, the current valuation is irrelevant if LABS epidiolex partner is trying to acquire LABS before generic approval. Because the valuation at which LABS will be acquired by their pharma partner will consider the potential growth related to its generic contract, if the path is somewhat clear for ANDA. If that generic contract is worth a projected 100M in annual revenue for LABS, they could factor in 80M/annually, offsetting some risk and offering X Market cap offer.
Any acquirer would be informed about the generic contract and would have to consider it in its offer.